Freenome

About

Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.

South San Francisco,California,United States
251 - 500
https://www.freenome.com

Highlights

Details

Last Funding Type: Corporate Round
Last Funding Money Raised: $290M
Industries: Biotechnology,Health Care,Health Diagnostics,Personal Health
Founded date: Jan 1, 2014
Number Of Employee: 251 - 500
Operating Status: Active
Legal Name: Freenome Inc.

Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages.

The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention.

Charles Roberts, Gabriel Otte, Riley Ennis, and Michael Otte launched the company in 2014 in South San Francisco, California.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

8

$1.09B

Freenome has raised a total of $1.09B in funding over 2 rounds. Their latest funding was raised on Jan 11, 2022 from a Corporate Round round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jan 11, 2022	Corporate Round	$290M	1	Roche	—	Detail
Dec 7, 2021	Series D	$300M	31	Perceptive Advisors RA Capital Management	—	Detail
Aug 26, 2020	Series C	$270M	22	Bain Capital Life Sciences Perceptive Advisors	—	Detail
Jul 24, 2019	Series B	$160M	16	Polaris Partners RA Capital Management	—	Detail
Aug 28, 2017	Series A	$7M	12	Section 32	—	Detail

Investors

Number of Lead Investors

Number of Investors

11

50

Freenome is funded by 50 investors. Roche and Perceptive Advisors are the most recent investors.

Investor Name	Lead Investor	Funding Round
Roche	Yes	Corporate Round
Perceptive Advisors	Yes	Series D
RA Capital Management	Yes	Series D
Loxbridge Research	Yes	Seed
Andreessen Horowitz	—	Series D
ArrowMark Partners	—	Series D
Artis Ventures (AV)	—	Series D
Bain Capital Life Sciences	—	Series D
BrightEdge Fund	—	Series D
Byers Capital	—	Series D